At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 101 enrolled
Drug / intervention
AC-170 0.05% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Efficacy of Three Different Concentrations of Cetirizine (0.05%, 0.1%, and 0.24%) Ophthalmic Solution Versus Vehicle in the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge Model (CAC)
In Brief
A Phase 3 clinical trial evaluating AC-170 0.05%, AC-170 0.1%, and 2 other interventions for Allergic Conjunctivitis. Completed, enrolled 101 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) Model.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedApr 2011
Primary CompletionJun 2011
Study CompletionOct 2011
TodayJul 2026
First PostedApr 11, 2011
Enrollment StartApr 1, 2011
Primary CompletionJun 1, 2011
Study CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.2 years ago
Interventions
AC-170 0.05%drug
1 drop in each eye at 3 separate times during a 21 day period
AC-170 0.1%drug
1 drop in each eye at 3 separate times during a 21 day period
AC-170 0.24%drug
1 drop in each eye at 3 separate times during a 21 day period
AC-170 0%drug
1 drop in each eye at 3 separate times during a 21 day period